The involvement of BRAF in podocyte survival in vitro is interesting and needs to be further understood considering that treatment with BRAF inhibitor, dabrafenib, associated with the development of nephrotic syndrome in melanoma patients and podocyte injury in vitro (45). This evidence concerns the gene BRAF and melanoma.